Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication

Oncogene

Volumn 25, Issue 20, 2006, Pages 2943-2949

  Duensing, A ^a,b   Liu, Y ^b   Tseng, M ^b   Malumbres, M ^c   Barbacid, M ^c   Duensing, S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

CDK2; Centrosome; Genomic instability; HPV 16 E7

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ALPHA TUBULIN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; GAMMA TUBULIN; PROTEIN E7; PROTEIN P107; PROTEIN P130; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CENTROSOME; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; FIBROBLAST; GENE DELETION; GENETIC TRANSFECTION; GENOMIC INSTABILITY; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; MITOSIS INDEX; MITOSIS SPINDLE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SPINDLE POLE BODY; WILD TYPE;

ANIMALS; CENTROSOME; CYCLIN-DEPENDENT KINASE 2; EMBRYO; FIBROBLASTS; GENE DUPLICATION; MICE; MICE, KNOCKOUT; ONCOGENE PROTEINS, VIRAL; RNA, SMALL INTERFERING;

ANIMALIA; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 33646710394     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209310     Document Type: Article

References (32)

1. Albrecht-Buehler G, Bushnell A. (1980). Exp Cell Res 126: 427-437.
2. Aleem E, Kiyokawa H, Kaldis P. (2005). Nat Cell Biol 7: 831-836.
3. Alvarez-Salas LM, Cullinan AE, Siwkowski A, Hampel A, DiPaolo JA. (1998). Proc Natl Acad Sci USA 95: 1189-1194.
4. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. (2003). Curr Biol 13: 1775-1785.
5. Bornens M. (2002). Curr Opin Cell Biol 14: 25-34.
6. Brinkley BR. (2001). Trends Cell Biol 11: 18-21.
7. Chen Z, Indjeian VB, McManus M, Wang L, Dynlacht BD. (2002). Dev Cell 3: 339-350.
8. Delattre M, Gonczy P. (2004). J Cell Sci 117: 1619-1630.
9. Doxsey S. (2002). Mol Cell 10: 439-440.
10. Duensing A, Geng Y, Sicinski P, Munger K, Duensing S. (2004a). Proc Am Assoc Cancer Res 45: 2596.
11. Duensing S. (2005). Cell Biol Int 29: 352-359.
12. Duensing S, Duensing A, Lee DC, Edwards KM, Piboonniyom S, Manuel E et al. (2004b). Oncogene 23: 8206-8215.
13. Duensing S, Lee LY, Duensing A, Basile J, Piboonniyom S, Gonzalez S et al. (2000). Proc Natl Acad Sci USA 97: 10002-10007.
14. Fisk HA, Winey M. (2001). Cell 106: 95-104.
15. Guarguaglini G, Duncan PI, Stierhof YD, Holmstrom T, Duensing S, Nigg EA. (2005). Mol Biol Cell 16: 1095-1107.
16. Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G. (1999). Science 283: 851-854.
17. Hinchcliffe EH, Sluder G. (2001). Genes Dev 15: 1167-1181.
18. Lacey KR, Jackson PK, Stearns T. (1999). Proc Natl Acad Sci USA 96: 2817-2822.
19. Mason DX, Jackson TJ, Lin AW. (2004). Oncogene 23: 9238-9246.
20. Matsumoto Y, Hayashi K, Nishida E. (1999). Curr Biol 9: 429-432.
21. Matsumoto Y, Maller JL. (2004). Science 306: 885-888.
22. Meijer L, Leclerc S, Leost M. (1999). Pharmacol Ther 82.
23. Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA. (1999). Nat Cell Biol 1: 88-93.
24. Munger K, Howley PM. (2002). Virus Res 89: 213-228.
25. Mussman JG, Horn HF, Carroll PE, Okuda M, Tarapore P, Donehower LA et al. (2000). Oncogene 19: 1635-1646.
26. Nigg EA. (2002). Nature Rev Cancer 2: 1-11.
27. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK et al. (2000). Cell 103: 127-140.
28. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R et al. (2003). Nat Genet 35: 25-31.
29. Salisbury JL, Whitehead CM, Lingle WL, Barrett SL. (1999). Biol Cell 91: 451-460.
30. Tetsu O, McCormick F. (2003). Cancer Cell 3: 233-245.
31. Wheatley DN, Wang AM, Strugnell GE. (1996). Cell Biol Int 20: 73-81.
32. Wong C, Stearns T. (2003). Nat Cell Biol 5: 539-544.